KRAS and non-small cell lung carcinoma: In another study, S. Mukhopadhyay used genome-wide CRISPR/Cas9 screening to identify genes whose inactivation enhances the efficacy of two drugs (MRTX-849: adagrasib, KRAS G12C Inhibitor; TNO-155: SHP2i, inhibitor of wild-type SHP2) in four NSCLC cell lines with KRAS/STK11-mutant NSCLC lines [53].